Drug Profile

METI 104

Alternative Names: METI-104

Latest Information Update: 28 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

28 Sep 2024 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in South Korea
07 Aug 2020 METI 104 is available for licensing as of 07 Aug 2020. http://www.metimedi.com/about/collaboration.php
07 Aug 2020 MetiMedi Pharmaceuticals in-licenses METI 104 from the Gachon University, prior to August 2020

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com